OncoMatch/Clinical Trials/NCT07284420
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Is NCT07284420 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Efgartigimod IV and Empasiprubart IV for achr-ab seropositive generalized myasthenia gravis.
Treatment: Efgartigimod IV · Empasiprubart IV — This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA1 is to evaluate the safety and therapeutic relevance of empasiprubart as add-on therapy to efgartigimod in participants with AChR-Ab seropositive generalized myasthenia gravis. The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Cannot have received: complement inhibitor (zilucoplan, eculizumab, ravulizumab)
Exception: if received within specified washout periods
Current administration of a complement inhibitor or received zilucoplan or eculizumab <2 months or ravulizumab <6 months before the first study drug administration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Profound Research LLC - Carlsbad · Carlsbad, California
- Visionary Investigators Network · Miami, Florida
- Dent Neurologic Institute - Amherst · Amherst, New York
- Erlanger Health System · Chattanooga, Tennessee
- National Neuromuscular Research Institute · Austin, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07284420 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior complement inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify